Folger Nolan Fleming Douglas Capital Management Inc. decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 2.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 122,864 shares of the company’s stock after selling 2,869 shares during the quarter. Johnson & Johnson makes up approximately 2.5% of Folger Nolan Fleming Douglas Capital Management Inc.’s holdings, making the stock its 4th largest holding. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Johnson & Johnson were worth $16,254,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. OLD Point Trust & Financial Services N A lifted its position in Johnson & Johnson by 2.2% during the 2nd quarter. OLD Point Trust & Financial Services N A now owns 61,326 shares of the company’s stock worth $8,113,000 after acquiring an additional 1,321 shares in the last quarter. Lynch & Associates IN lifted its position in Johnson & Johnson by 0.9% during the 2nd quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock worth $12,397,000 after acquiring an additional 841 shares in the last quarter. Welch & Forbes LLC lifted its position in Johnson & Johnson by 0.9% during the 2nd quarter. Welch & Forbes LLC now owns 718,331 shares of the company’s stock worth $95,028,000 after acquiring an additional 6,730 shares in the last quarter. Oakbrook Investments LLC lifted its position in Johnson & Johnson by 7.4% during the 2nd quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock worth $18,008,000 after acquiring an additional 9,375 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its position in Johnson & Johnson by 0.5% during the 2nd quarter. Janney Montgomery Scott LLC now owns 771,868 shares of the company’s stock worth $102,110,000 after acquiring an additional 3,533 shares in the last quarter. Institutional investors own 65.90% of the company’s stock.

Several equities analysts recently commented on JNJ shares. J P Morgan Chase & Co boosted their price target on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 16th. Jefferies Group set a $145.00 price target on Johnson & Johnson and gave the stock a “hold” rating in a research report on Tuesday, August 15th. Cowen set a $147.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research report on Thursday, August 24th. UBS reaffirmed an “underweight” rating on shares of Johnson & Johnson in a research report on Thursday, August 24th. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $145.00 target price on shares of Johnson & Johnson in a research report on Friday, September 1st. Four analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $144.59.

Shares of Johnson & Johnson (NYSE JNJ) traded down $1.05 on Friday, reaching $140.01. The company had a trading volume of 4,713,100 shares, compared to its average volume of 5,871,539. The company has a market cap of $378,960.50, a P/E ratio of 19.76, a P/E/G ratio of 2.87 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a 52-week low of $109.93 and a 52-week high of $144.35.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The firm had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. During the same period in the prior year, the business earned $1.68 EPS. The firm’s revenue was up 10.3% on a year-over-year basis. equities analysts predict that Johnson & Johnson will post 7.28 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a $0.84 dividend. The ex-dividend date is Monday, November 27th. This represents a $3.36 annualized dividend and a dividend yield of 2.40%. Johnson & Johnson’s payout ratio is 58.33%.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/12/08/johnson-johnson-jnj-position-reduced-by-folger-nolan-fleming-douglas-capital-management-inc.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.